Risk of Germ Cell Tumors among Men with HIV/Acquired Immunodeficiency Syndrome

Goedert, James J.; Purdue, Mark P.; McNeel, Timothy S.; McGlynn, Katherine A.; Engels, Eric A.

doi:10.1158/1055-9965.epi-07-0042

Cited by 38 publications

(34 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Additionally, several genitourinary malignancies have been demonstrated to have an increased incidence in the HIVpositive population, including testicular seminoma and renal cell carcinoma. [8][9] This has been postulated to be a result of immunosuppression; however, these interactions have yet to be fully understood.…”

Section: Introductionmentioning

confidence: 99%

Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus

Silberstein

Parsons

Palazzi-Churas

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The aim of this study is to evaluate the outcomes of robot-assisted laparoscopic prostatectomy (RALP) in prostate cancer (PCa) patients with human immunodeficiency virus (HIV). This is a prospective cohort study of HIV patients undergoing RALP, comparing the demographics, tumor characteristics, complications, and short-term oncological outcomes of HIV-positive men to HIV-negative men using univariate (v 2 , Mann-Whitney test) and multivariable (logistic regression) analyses. From 2007 to 2010, 298 men underwent RALP, 8 of whom were known to be HIV positive. Preoperatively, all eight were taking highly active antiretroviral therapy (HAART) and had undetectable viral loads (o50); mean CD4 count was 634 cells per mm 3 . HIV-positive men were younger (54 versus 62 years, P ¼ 0.010) and less likely to be white (P ¼ 0.007). There were no significant differences between groups with respect to clinical staging, pathological and oncological outcomes or most complication rates. However, the prevalence of perioperative transfusions (P ¼ 0.031) and ileus (P ¼ 0.021) were higher in HIV-positive patients. HIV remained significantly associated with risk of transfusion after adjustment for age, race, Gleason sum and clinical T stage (P ¼ 0.002). After a median of 2.6 (range 0.03-19.2) months of follow-up, PSA remained undetectable in all eight HIV patients. These data suggest that RALP is safe for, and demonstrates short-term oncological efficacy in, HIV-positive patients with PCa.

show abstract

Section: Introductionmentioning

confidence: 99%

Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus

Silberstein

Parsons

Palazzi-Churas

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…1 In addition, several genitourinary malignancies have been demonstrated to have an increased incidence in the HIV-positive population including seminoma and possibly renal cell carcinoma. 1,2 Interestingly, some malignancies such as breast cancer have been shown to occur at a reduced rate in this population. 3 According to the Centers of Disease Control, at the end of 2003 an estimated 1 039 000-1 185 000 persons in the United States were living with HIV/AIDS and about three quarters of these patients were men.…”

Section: Introductionmentioning

confidence: 99%

HIV and prostate cancer: a systematic review of the literature

Silberstein

Downs

Lakin

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Malignancy occurs with increased frequency in the HIV-positive population. The true incidence of prostate cancer in this population is unknown. In the few cases that have been presented in the literature, prostate cancer in HIV-positive men appears to behave much like it does in HIV-negative men. Prostate cancer is the most common malignancy in men and the second leading cause of cancer death. Approximately 800 000 men in the United States are HIV positive, and innovative therapies have dramatically improved survival. HIV disproportionately impacts ethnic groups with increased risk of prostate cancer and has been associated with increases in the incidence of certain malignancies. Despite the high prevalence of both diseases, there is relatively little literature about prostate cancer in HIV-positive patients. There is no consensus on how to screen or treat this patient population. We review the literature with regards to incidence, screening, treatment, and outcomes of this poorly characterized population. We briefly discuss the impact of highly active antiretroviral therapy and testosterone supplementation in the development of prostate cancer. A systematic review of the literature was conducted using MEDLINE key words 'HIV,' 'prostate,' 'prostate cancer' and 'AIDS.' Manual bibliographic review of cross-referenced items was also performed. A total of 176 unique abstracts and publications were reviewed; many authors provided data on the incidence of HIV and various malignancies including prostate cancer. Twelve unique publications providing detailed information on 60 patients with HIV and prostate cancer were identified. Prostate cancer is a common malignancy in HIV-positive men. With improved therapies for HIV and increasing survival, the importance for screening and treating prostate cancer is increasing. Acute outcomes of treatment do not demonstrate increased acute morbidity; however long-term outcomes have not been reported.

show abstract

“…74 Despite the high prevalence of HIV infection in sub-Saharan Africa, there have been no reports of a significant increase in germ cell testicular tumors in this region. A more recent study indicated that the relative risk for testicular seminoma in HIV-positive patients compared with HIV-negative individuals is around 2.…”

Section: Testicular Tumorsmentioning

confidence: 99%